Company intelligence / Profile preview
Advanced Accelerator Applications
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
Overview
Advanced Accelerator Applications has several approved diagnostic and therapeutic radiopharmaceuticals, notably for neuroendocrine tumors and prostate cancer. Its lead therapy Lutathera® was approved in the US in March 2018 for GEP-NETs. The company continues to expand its manufacturing footprint globally to support both marketed products and pipeline candidates. Recent clinical results include successful Phase I studies of novel PSMA-targeted PET imaging agents.
- Therapeutic areas
- OtherOncologyInfectious Diseases
- Modalities
- Peptide conjugate radionuclidesDiagnostic radiopharmaceuticalsTherapeutic radiopharmaceuticalsSmall molecule drugs
- Industry
- Biotech
Drug pipeline
21 assets20 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Advanced Accelerator Applications.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Advanced Accelerator Applications.